In The News

Catalyst OrthoScience is counting on clinical research to show that its stemless shoulder arthroplasty system promotes faster healing and the restoration of a patient’s normal range of motion. Shoulder arthroplasty technology has not changed much since Charles Neer first developed total shoulder implants in the 1950s and 1960s,  Matthew Budge, an orthopedic surgeon…

Learn more why Catalyst was ranked one of the top ten startup companies in 2022 by Medtech Outlook. https://www.medicaltechoutlook.com/catalyst-orthoscience

Updated on Monday, October 3: Power has been restored to all Southwest Florida Catalyst facilities and our offices reopened today. Our Customer Service department is processing orders and our Distribution Center continues to fulfill orders and customer needs from our back-up location in Southeast Florida to ensure that any shipments…

Catalyst OrthoScience initiates a controlled, limited user release of the planning software to test the software in clinical settings NAPLES, Fla., March 21, 2022 – Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, today announced that the platform technology for its Archer™ 3D…

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has named Carl O’Connell as president and chief executive officer effective immediately. O’Connell replaces Brian Hutchison, who is stepping down. Hutchison joined the company as executive chairman and interim CEO in June 2018 before being asked…

"Despite an up-and-down year, Catalyst Orthoscience appears poised for takeoff in the new year. One big aid? It has a product surgeons and patients alike love." View Article, Dec 20, 2021

Catalyst OrthoScience has received clearance from the U.S. Food & Drug Administration to market its reverse shoulder system. Catalyst expects to begin a limited user release in the United States in the second quarter of 2021 followed by a commercial launch later in 2021.

Catalyst OrthoScience has received clearance from the U.S. Food & Drug Administration to market its reverse shoulder system. Catalyst expects to begin a limited user release in the United States in the second quarter of 2021 followed by a commercial launch later in 2021.

Catalyst OrthoScience has received clearance from the U.S. Food & Drug Administration to market its reverse shoulder system. Catalyst expects to begin a limited user release in the United States in the second quarter of 2021 followed by a commercial launch later in 2021.

Published peer reviewed study show significant improvements in motion and patient-reported measures in adult shoulder replacement patients of all ages.